Gentian Diagnostics ASA · OSL:GENT
Gentian Diagnostics ASA — Investor Presentation (December 2016)
22 slides from Gentian Diagnostics ASA's investor presentation, Dec 14, 2016

Slide 1: Corporate presentation
Corporate presentation December 2016

Slide 2: Improving Clinical Accuracy
Improving Clinical Accuracy 1 Introduction 2 Existing business 3 Pipeline opportunities 4 Financials

Slide 3: Building a leading diagnostics company
Building a leading diagnostics company Gentian Diagnostics Team has previously founded Axis-Shield (sold to Alere for $ 367M) Five tests on the market with international customer base Significant pipeline including near-term launches Fully funded for all planned development activities Stro

Slide 4: Medical diagnostics at a glance
Medical diagnostics at a glance Results sent to Sample collection Transport to lab Analysis Diagnosis physician Gentian develops reagent consumables for analytical instruments Chemistry is instrument independent Can be used on existing infrastructure

Slide 5: Gentian operates in a highly attractive market
COMPANY PRESENTATION Gentian operates in a highly attractive market Large (50 B USD) 19% 45% CAGR: 5.8% 24% Stable

Slide 6: Gentian addresses unmet needs in the market
Gentian addresses unmet needs in the market Gentian R&D Faster results to New tests for patients better diagnostics Improving efficacy and costs for labs

Slide 7: Introduction Existing business Pipeline opportunities
1 Introduction 2 Existing business 3 Pipeline opportunities 4 Financials

Slide 8: Management team with track record
Management team with track record The Management Team Bård Henrik Sundrehagen Erling Sundrehagen Ole Benny Østby Chief Executive Officer Chief Scientific Officer V.P. QA/RA 12 years Gentian M.D. & PhD 3 years Gentian 9 years Axis-Shield Founded Axis Shield in 1984, QA Supervisor Axis-Shi

Slide 9: Commercial stage company built step by step
Commercial stage company built step by step Proven R&D capabilities and commercial operations • Five products developed and launched • Total revenue of MNOK ~30 with gross margin of 70% • Positive cash flow ex R&D • Built significant pipeline

Slide 10: Established infrastructure funded by existing products
Established infrastructure funded by existing products

Slide 11: Launched products with global distribution
Launched products with global distribution Cystatin C – Marker for diagnosis of early stage kidney disease – Distributed by Beckman Coulter and national market players Fecal calprotectin – Marker for inflammatory bowel disease – Distributed by Bühlmann Lab’s, international market leader NGAL –

Slide 12: Improving Clinical Accuracy
Improving Clinical Accuracy 1 Higher sensitivity => Higher volumes 2 New tests 3 Pipeline opportunities 4 Financials

Slide 13: Highly efficient development process
Highly efficient development process Development process 3.5 years Proof of concept Optimisation Verification Validation Launch 6 months 12 months 6 months 6 months 12 months Total average project cost: MNOK 8

Slide 14: Selected pipeline projects
Selected pipeline projects Plasma calprotectin – Test for early detection of inflammation – Potentially a superior marker for sepsis – Substantial unmet medical need – Launch in 2017 G-1001 – Current market size 2016E: c150 million tests performed annually – CAGR: 15% – Target launch 2018/19 – M

Slide 15: Improving Clinical Accuracy
Improving Clinical Accuracy 1 Higher sensitivity => Higher volume 2 New tests 3 New technologies 4 Financials

Slide 16: Financials: Solid base with substantial upside
Financials: Solid base with substantial upside 1 2 Base business Pipeline opportunity Revenues of MNOK ~30 Expect to launch one product per year on CAGR of 20% over the last 5 years average from 2017 Positive cash flow ex. R&D Total pipeline addresses market of >$3bn/y Solid cash positio

Slide 17: Significant news flow expected
Significant news flow expected Proofs of concept Product Launches Quarterly reports Significant Publications Patent news Sales contract and market penetrations

Slide 18: Strategy supported by very strong shareholder base
Shareholderlist as of 12.12.2016 Strategy supported by very strong shareholder base Shareholder # of shares % shares Sundrehagen family 3 611 350 32,42 % Holta Life Sciences AS 1 928 496 17,31 % Rasmussengruppen AS 1 379 990 12,39 % Storebrand Vekst Verdipapirfond 1 030 420 9,25 % Kristianro AS, Eig

Slide 19: Improving Clinical Accuracy
Improving Clinical Accuracy

Slide 20: Important notice
Important notice This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The

Slide 21: Questions?
Questions?

Slide 22: entian
entian gen Clinical Accuracy
Source: Internet Archive copy of gentian.no
More decks from Gentian Diagnostics ASA
Q3 2026 Earnings Presentation35 slides · Oct 20, 2026
Q2 2026 Earnings Presentation33 slides · Jul 9, 2026
Q1 2026 Earnings Presentation35 slides · May 6, 2026
Q4 2025 Earnings Presentation37 slides · Feb 11, 2026
DNB Nordic Healthcare Conference 202524 slides · Nov 25, 2025
Q3 2025 Earnings Presentation35 slides · Oct 23, 2025